Indian researchers have developed an artificial intelligence tool that uses deep learning to identify cancer stem-like cells that can remain difficult to detect within tumours, adding to the growing use of AI for analysing complex biological data.
Called ACCSeND, the tool has been developed by scientists from Ashoka University and the S.N. Bose National Centre for Basic Sciences. It is designed to distinguish cancer stem-like cells by analysing complex biological patterns and cellular characteristics that may be difficult to identify through conventional approaches.
Cancer stem-like cells have become an important area of oncology research because they are associated with tumour development, progression and resistance to treatment. Their ability to persist within tumour environments can make them particularly relevant to studies examining why some cancers recur or respond differently to therapies.
ACCSeND applies deep learning to the identification process, allowing researchers to analyse biological information and recognise patterns linked to these cells. According to the report, the system demonstrated stronger performance than several existing methods used to identify cancer stem-like cells.
The development does not mean that ACCSeND is currently a replacement for established cancer diagnostic procedures. The technology is positioned as a research tool that could help scientists investigate tumour biology and cellular behaviour in greater detail.
Its development comes as artificial intelligence is increasingly being applied across cancer research, including medical imaging, digital pathology, genomic analysis and the classification of cells and tissues.
Deep learning models are particularly suited to analysing large datasets where relationships between individual features can be difficult to detect manually. In cancer research, these systems can be trained to recognise biological and morphological patterns that may help researchers categorise cells or investigate differences within tumour environments.
Recent oncology research has similarly examined the use of AI across imaging, pathology and multi-omics data, reflecting a broader move towards combining computational techniques with biological research.
For researchers, identifying cancer stem-like cells more accurately could support studies into how tumours develop and why certain cell populations survive treatment. This could also contribute to research examining treatment resistance and potential therapeutic targets.
The technology is relevant to the wider development of precision medicine, which seeks to understand disease at increasingly detailed molecular and cellular levels rather than treating every tumour of the same cancer type as biologically identical.
ACCSeND also highlights the expansion of AI-led biomedical research within India. Ashoka University and the S.N. Bose National Centre for Basic Sciences are combining computational approaches with life sciences research to address a problem that depends on identifying subtle cellular differences.
However, translating research tools into clinical applications requires further validation. Performance in research settings does not automatically establish how a system will perform across different patient populations, laboratories or real-world clinical environments.
For now, ACCSeND represents another application of deep learning beyond generative AI, using pattern recognition to analyse biological data rather than generate content.
As AI becomes more integrated with biomedical research, tools such as ACCSeND could help researchers examine cancer at a more granular level. Their eventual clinical relevance, however, will depend on further research, validation and evidence demonstrating that their performance can translate reliably into healthcare settings.